Tagged Articles

Colcrys 2 articles

Actos maker to buy gout treatment manufacturer

Japanese drug maker Takeda Pharmaceuticals Co. is hoping an $800 million acquisition of U.S. gout treatment maker URL Pharma Inc. will boost the company’s U.S. sales and, ideally, cover ground lost with its blockbuster type 2 diabetes drug Actos. Not only does Actos lose its patent protection later this year, paving the way for generic competition, sales of the drug have slumped since last year, when the Food and Drug Administration (FDA) warned that studies have linked the diabetes treatment to bladder cancer. Takeda is Japan’s largest drug maker, but the majority of its sales come from the United States ... Read More

Actos maker Takeda buys U.S. gout drug manufacturer

Japanese pharmaceutical giant Takeda, which produces the controversial diabetes drug Actos, is expanding its U.S. reach with an $800-million takeover of URL Pharma Inc. The move comes as Takeda’s U.S. profits are set to contract after Actos loses its patent protection later this year. Among other drugs, Philadephia-based URL manufactures Colcrys, an oral drug that is used to treat gout flare-ups. Colcrys is URL’s top moneymaker, earning the company $430 million in revenue last year. Takeda is Japan’s largest pharmaceutical company, but most of its sales revenues come from the United States, according to the Associated Press. Its top-earning drug ... Read More